

Relating Recent Infection Prevalence to Incidence with a Sub-population of Non-progressors.

Thomas McWalter* and Alex Welte†

October 29, 2022

Abstract

We present a new analysis of relationships between disease incidence and the prevalence of an experimentally defined state of ‘recent infection’. This leads to a clean separation between *biological* parameters, which are sought by calibration, and *epidemiological* parameters, which are sought in an inference of incidence. The framework takes into account the possibility that details of the assay and host/pathogen chemistry leave a (knowable) fraction of the population in the recent category for all times. This systematically addresses an issue which is the source of some controversy about the appropriate use of the BED assay for defining recent HIV infection. Analysis of relative contributions of error arising variously from statistical considerations and simplifications of general expressions indicate that statistical error dominates heavily over all sources of bias in the experimentally interesting regime. Numerical calculations validate the approximations made in analytical relations.

*School of Computational and Applied Mathematics, University of the Witwatersrand, South Africa

†Corresponding author; DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) and School of Computational and Applied Mathematics, University of the Witwatersrand, South Africa

1 Introduction

Reliable estimation of disease *incidence* (rate of occurrence of new infections) and *prevalence* (the fraction of a population in an infected state at a point in time) are central to the determination of epidemiological trends, especially for the allocation of resources and evaluation of interventions. Prevalence estimation is relatively straightforward, for example by cross-sectional survey. Incidence estimates are notoriously problematic, though potentially of crucial importance. An approximate measure of incidence in a population is required for the proper planning of sample sizes and costing for clinical trials and other population based studies. Repeated follow-up of a representative cohort is often touted as the ‘gold standard’ for estimating incidence, but is costly, time intensive and still prone to some intrinsic problems. For example, there is potentially bias in the factors determining which subjects are lost to follow-up. Furthermore, ethical considerations demand that a cohort study involve substantial support for subjects to avoid becoming infected, which may make the cohort unrepresentative of the population of interest.

Numerous methods have been proposed for inferring incidence from single or multiple cross-sectional surveys rather than following up a cohort [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]. A central idea in some of these is to count the prevalence of some state of ‘recent infection’, which naturally depends on the recent incidence. The relationship between the two is in general not simple and depends in detail on the recent population dynamics as well as distributions which capture the inter-subject variability of progression through stages of infection, as they are observed by the specific laboratory assays used in the test for recent infection (TRI). For this approach to be sensible, a working definition of ‘recent infection’ must be calibrated, for example by repeatedly following up subjects over a period during which they become infected. This is effectively as much effort as one measurement of incidence by follow-up. The calibration could in principle be used to infer incidence from each of many subsequent independent cross-sectional surveys.

Owing to the devastating impact of the HIV epidemic, and the many challenges of research and intervention design, the problem of estimating HIV incidence has attracted considerable interest in recent years. The prospect of using a TRI is in principle very attractive. Given the range of values of incidence likely to be observed in populations with a major epidemic (say 1-10% p.a.) a mean definition of ‘recent’ of approximately half a year is required to yield reasonable statistical confidence for sample sizes of a few thousand. The BED assay is currently the leading candidate for such a test, but controversy has arisen about the possibility of conducting a reliable calibration. This stems from the fact that a subset of individuals (approximately 5% [10], potentially variable between viral and host populations) fail to progress above any statistically useful threshold set on the assay in the definition of ‘recent’ infection. This subset of individuals who consequently remain classified as ‘recently infected’ for all times poses a problem to which there is currently no consensus remedy.

We present a new analysis of the interaction between epidemiological trends and a model of inter-subject variability of progression through an experimental category of ‘recent infection’. Our model yields simple formulas for inference *even when a fraction of the population fails to progress out of the recent category*. The only physiological assumption required to deal with the non-progressors is that their survival after infection is the same as the progressors.

The article is organised as follows. In Section 2 we first develop a basic differential equation model defined by a time dependent incidence and susceptible population, a distribution of times after infection spent below threshold on a TRI and a distribution of

post-infection survival times. We note that there is in principle no specific relationship between the instantaneous incidence and a prevalence of infected, but below-threshold, individuals. At best, one obtains a relationship between the below-threshold prevalence and a convolution of the recent incidence with a specific weighting function which is implied by the use of a TRI. This relationship in principle includes all moments of the distribution of the waiting times that individuals spend below threshold. We show that, for realistic rates of variation in the susceptible population, only the mean of the waiting time distribution is needed, and a simple expression for a weighted average of the incidence is obtained. The basic model is extended to allow some fraction of individuals (a new parameter) to be assigned infinite waiting times below the threshold of the TRI. This leads to only very minor modifications of the previous expression for weighted incidence, namely a systematic ‘subtraction’ of over-counted ‘not recently infected’ individuals which are included in the experimental category ‘below threshold’. This subtraction is similar, but not identical, to corrections proposed in other articles on the subject.

Section 3 explores the consequences of designing a cross-sectional survey with a sample size N based on the relations derived in Section 2. Using a systematic expansion of the incidence estimator in powers of $1/\sqrt{N}$ (derived in the Appendix), we note consistency of the estimator (no bias in the limit of large N) and derive an approximate expression for its relative variance. These expressions facilitate error estimation both from a study design and data analysis point of view. On calibration, we note that trends, as opposed to absolute values, for incidence can be obtained without any information about the distribution of finite waiting times below threshold. However, an estimate of the fraction of non-progressors is essential. A key observation is that statistical error, for realistic population dynamics and sample sizes, is much larger than all the sources of bias.

Numerical simulations are presented in Section 4. These demonstrate that the approximate statistical analysis of Section 2 is essentially correct, with discrepancies of the size expected from the $1/\sqrt{N}$ expansion.

In the conclusion, we note that the framework presented here is quite general and is applicable to any TRI, as long as any finite probability for non-progression can be calibrated, survival is the same for progressors and non-progressors, and there is no ‘relapse’ from above to below the recency threshold. It may be possible to modify the analysis to relax these requirements. We point out some differences between the present analysis and other proposals for using the BED TRI for measuring HIV incidence, which could be more systematically investigated.

2 Relating the Prevalence of ‘Recent Infection’ to Incidence

We now outline a quite general approach to relating the key demographic, epidemiological and biological processes which are relevant to the estimation of incidence from cross-sectional surveys of the prevalence of ‘recent infection’. This refines the naive intuition that a high prevalence of ‘recently infected’ individuals means a high incidence.

The Basic Model

Consider an assay which yields a quantitative result, the value of which typically increases with time from infection. The BED assay is of this type, with the quantitative

result being an optical density (OD). The hypothetical ongoing observation of an individual might lead to a curve similar to that displayed in Figure 1A. Such an assay becomes a test for recent infection when we declare a threshold value and define ‘observed to be recently infected’ to be a test value below the threshold.

In practice, there is inevitably inter-individual variation in these progression curves. Plotting the curves for multiple individuals on a single graph would lead to something like Figure 1B. Clearly, the category ‘observed to be recently infected’ is not sharply defined by a time boundary, and we now adopt the more precise labels *below* threshold (B) and *above* threshold (A). The variability of times spent in the below-threshold category, for a given threshold OD, can be summarised by a distribution of waiting times f_B which may look something like that shown in Figure 1C.

It is now possible to construct a basic epidemiological model shown in Figure 3A. Individuals move from the *susceptible* population $S(t)$ to the infected below-threshold population $B(t)$, where they remain for a waiting time distributed according to a probability density given by f_B , before moving to the above-threshold population $A(t)$. We denote by τ_B a waiting time generated according to the density f_B . The corresponding cumulative probability function is given by

$$F_B(t) = \int_{-\infty}^t f_B(s) ds, \quad (1)$$

while the probability of ‘survival’ (persistence) in the population B *conditional on being alive* is

$$L_B(t) = \mathbb{P}(\tau_B > t) = 1 - F_B, \quad (2)$$

and the mean waiting time is

$$\mathbb{E}[\tau_B] = \int_0^{\infty} \tau f_B(\tau) d\tau. \quad (3)$$

Analogously, we define f_L , τ_L , F_L , L_L and $\mathbb{E}[\tau_L]$ in order to specify *lifetimes* of individuals after the moment of infection. We assume that survival time and waiting time to threshold are independent in this model. Hence, the probability, at a time delay Δt after infection, of being *simultaneously* living and below threshold on the assay is

$$\mathbb{P}(\tau_L > \Delta t \text{ AND } \tau_B > \Delta t) = L_{LB}(\Delta t) = L_L(\Delta t)L_B(\Delta t). \quad (4)$$

Similarly, the probability of being *simultaneously* living and above threshold is

$$\mathbb{P}(\tau_L > \Delta t \text{ AND } \tau_B < \Delta t) = L_L(\Delta t)(1 - L_B(\Delta t)). \quad (5)$$

New infections are generated by a non-homogeneous Poisson process with an intensity (probability per unit time of new arrivals) $\lambda(t)$. Let the incidence be given by $I(t)$. Then, in a period dt around time t , the expected number of new infections dI is given by

$$dI = \lambda(t) dt = I(t)S(t) dt. \quad (6)$$

We can now write down numerous expressions resulting from the model. For example, the expected number of historically infected persons accumulated up until time t is given by

$$H(t) = \int_{-\infty}^t \lambda(s) ds = \int_{-\infty}^t I(s)S(s) ds. \quad (7)$$

The expected populations of infected persons below and above threshold at time t are

$$\begin{aligned} B(t) &= \int_{-\infty}^t I(s)S(s)\mathbb{P}(\tau_L > t - s \text{ AND } \tau_B < t - s) ds \\ &= \int_{-\infty}^t I(s)S(s)L_{LB}(t - s) ds \end{aligned} \quad (8)$$

and

$$\begin{aligned} A(t) &= \int_{-\infty}^t I(s)S(s)\mathbb{P}(\tau_L > t - s \text{ AND } \tau_B > t - s) ds \\ &= \int_{-\infty}^t I(s)S(s)L_L(t - s)(1 - L_B(t - s)) ds. \end{aligned} \quad (9)$$

Our goal is to relate I for recent times to instantaneous values of B , A and S . We wish to emphasize the cautionary note that there is *fundamentally* a loss of information when one tries to characterise the history of a population based on observations made at a single time point. The recent historical course of a population, and even *instantaneous* values of state variables which are *rates*, like incidence, are in general not inferable from *counting* data obtained in a single survey. This is due to the fact that counts are, unavoidably, convolutions of historical epidemiological variables, as in (8) and (9) above. Any attempt to derive incidence estimates from the counting of infections accumulated in the recent past faces this problem, and at best some sort of weighted average of the recent values of incidence can be inferred without additional special assumptions.

In general, a well defined construction of a point estimate for incidence at time t will be some sort of weighted average of past values

$$I_w(t) = \frac{\int_{-\infty}^t I(s)W(s, t) ds}{\int_{-\infty}^t W(s, t) ds}, \quad (10)$$

where $W(s, t)$ is a statistical weight dependent on a convolution of population history and biology. Since our goal is to estimate incidence from a count of recently infected individuals, a natural weighting function is one that reflects the relative contributions to this count made by infections from different times in the recent past. Hence, we consider

$$W(s, t) = S(s)L_{LB}(t - s) \quad (11)$$

since $W(s, t)$ is proportional to the probability, at time $s < t$, that individuals are

1. available for being infected,
2. still living at time t if they are infected around time s , and
3. classified as below threshold at time t if they become infected at time s and are living at time t .

Using (11) as the weighting function leads to an expression for the incidence given by

$$\begin{aligned} I_w(t) &= \frac{\int_{-\infty}^t I(s)S(s)L_{LB}(t - s) ds}{\int_{-\infty}^t S(s)L_{LB}(t - s) ds} \\ &= \frac{B(t)}{\int_{-\infty}^t S(s)L_{LB}(t - s) ds}. \end{aligned} \quad (12)$$

The numerator in this expression is an instantaneous state variable, while the denominator in principle involves data from the entire history of the system as well as full knowledge of the survival function L_{LB} .

Simple Expression for Incidence

A simplified expression for weighted incidence in terms of sample and calibration data is now derived. We express the susceptible population using the expansion

$$S(t) = S_0 + S_1 t + S_2 t^2 + \dots \quad (13)$$

and use the identity

$$\int_{-\infty}^0 s^n L_{\text{LB}}(-s) ds = \frac{(-1)^n}{n+1} \mathbb{E} [\tau_{\text{LB}}^{n+1}], \quad (14)$$

which follows directly from integration by parts. For simplicity we consider incidence estimation at time $t = 0$, in which case we have

$$\begin{aligned} I_{\text{W}} &= \frac{B_0}{\int_{-\infty}^0 S(s) L_{\text{LB}}(-s) ds} \\ &= \frac{B_0}{S_0 \mathbb{E} [\tau_{\text{LB}}] - \frac{S_1}{2} \mathbb{E} [\tau_{\text{LB}}^2] + \dots} \end{aligned} \quad (15)$$

where $B_0 = B(0)$.

If the susceptible population is approximately constant for the times where the weight W is non-vanishing, we obtain the simple relation

$$I_{\text{W}} = \frac{B_0}{S_0 \mathbb{E} [\tau_{\text{LB}}]}, \quad (16)$$

which gives a weighted recent incidence in terms of instantaneous state variables (B_0 and S_0) and the expected waiting time in the below-threshold category.

Expectation values of the form $\mathbb{E} [\tau_{\text{LB}}^n]$ are not state variables and should in principle be measured independently of a particular cross-sectional survey. Usually this would be accomplished in a calibration cohort follow-up study. Thus, after calibrating some expectation values of f_{LB} , we can deal with a truncated expansion for $S(t)$ without further assumptions about the behavior of $I(t)$.

Some cautionary comments on calibration are, however, necessary. It seems unlikely that accurate measurements for terms of higher order than just $\mathbb{E} [\tau_{\text{LB}}]$ are practically possible. Finding the non-leading terms S_i (for $i > 0$) in the expansion of $S(t)$ will also require considerable demographic research.

These considerations mean that it is most likely that we will be constrained to use the simple expression (16) even if the susceptible population is not approximately constant over the times where W is non-vanishing. The key question then is: how severe is the bias introduced by using the simple formula under realistic non-constancy of the susceptible population?

In order to explore this issue systematically we consider a non-constant susceptible population given by $S(t) = S_0 e^{\alpha t}$. This has a conveniently tunable degree of failure to conform with the constancy assumption required for (16). When $\alpha = 0$ we have a constant number of susceptibles, while a value of $\alpha = \ln(f)$ means the population grows by a factor of f in one year. We can provide a survival function $L_{\text{LB}}(t)$, roughly inspired by the OD progression on the BED assay, by specifying f_{LB} to be a Weibull distribution with scale parameter $l = 0.57$ and shape parameter $k = 8$. We now numerically evaluate the denominator of (15) and compare it to the denominator of the simple formula (16). Note that this bias calculation is independent of the actual time dependence in $I(t)$.

In Figure 2, the bias in the naive denominator (reported as a fraction of the unbiased denominator) is shown as a function of α , reported as the annual percentage growth. Note that for a population growing at 4% per year, the bias is about 1.1%. As we shall see later when analysing a slightly more complex model of a TRI, this is small compared with the statistical error that arises as a result of using realistic sample sizes. Thus, bias arising from the non-constancy of the susceptible population is not a key concern unless there is very dramatic variation in $S(t)$. The bias calculation demonstrated here is also applicable to the more complex model that now follows.

Modelling Non-progressing Individuals

A complicating factor for the BED assay is the fact that a small number of individuals utterly fail to progress beyond any practical OD threshold used to define recency. This is due to individual variation in biochemical details such as immune response, for example. The non-progression phenomenon leads to a long term accumulation of *apparently* recently infected individuals, as classified by the TRI, even though many of them have been infected for a long time. There is currently no consensus on how to handle this complication. We now generalise the previous analysis to the situation where some individuals fail to progress to the above-threshold category.

Consider the simple model captured in Figure 3B. At the moment of infection, individuals transition from the susceptible population to either a non-progressing population (NP) or to a progressing below-threshold population (P_B). The probability of non-progression is \mathbb{P}_{NP} , and hence the probability of progression is $1 - \mathbb{P}_{NP}$. Those individuals in P_B wait for a stochastic delay, generated by a density f_B , after which they move into the above-threshold category P_A . Note that now we can only define a properly normalised f_B on the progressing sub-population.

The difficulty is that the TRI will classify as ‘recently infected’ all the individuals in the NP *and* P_B categories even though some potentially large number in NP are long infected. This can systematically be addressed by the following two key steps.

Firstly, we assume that the same survival function L_L is applicable to both progressing and non-progressing individuals. This is true if the differences between individuals which account for progression versus non-progression do not translate into significant differences in post-infection survival. The applicability of this assumption should in principle be tested, but we are unaware of any evidence that suggests it is false.

Secondly, we introduce two artificial categories by separating the non-progressing population into ‘recently infected’ (NP_R) and ‘long infected’ (NP_L) sub-populations. Individuals entering the NP_R sub-population are assigned a waiting time drawn from f_B after which they transition to the NP_L category. Note that this is a book-keeping device used for convenience and, unlike the assumption about survival, does not rely on any property of disease progression.

These two assumptions lead to the model in Figure 3C. It is now possible to recycle our preceding analysis and write down expected counts in these new classes. For the progressing populations we obtain

$$P_B(t) = (1 - \mathbb{P}_{NP}) \int_{-\infty}^t I(s)S(s)L_{LB}(t-s) ds \quad (17)$$

and

$$P_A(t) = (1 - \mathbb{P}_{NP}) \int_{-\infty}^t I(s)S(s)L_L(t-s)F_B(t-s) ds, \quad (18)$$

much as we obtained for $B(t)$ and $A(t)$ in the basic model up to the factor $(1 - \mathbb{P}_{\text{NP}})$. Furthermore, for the non-progressing populations we obtain

$$NP_{\text{R}}(t) = \mathbb{P}_{\text{NP}} \int_{-\infty}^t I(s)S(s)L_{\text{LB}}(t-s) ds \quad (19)$$

and

$$NP_{\text{L}}(t) = \mathbb{P}_{\text{NP}} \int_{-\infty}^t I(s)S(s)L_{\text{L}}(t-s)F_{\text{B}}(t-s) ds. \quad (20)$$

For convenience we define

$$\epsilon = \frac{\mathbb{P}_{\text{NP}}}{1 - \mathbb{P}_{\text{NP}}}, \quad (21)$$

and note that

$$NP_{\text{R}}(t) = \epsilon P_{\text{B}}(t) \quad (22)$$

and, more importantly,

$$NP_{\text{L}}(t) = \epsilon P_{\text{A}}(t). \quad (23)$$

These equations express a symmetry between the progressing and non-progressing sub-populations of Figure 3C. This results from the fact that the two branches use the same distributions f_{B} and f_{L} .

It is now possible to provide a sensible definition for the class of ‘recently infected individuals’, namely R , which has a population given by

$$R(t) = P_{\text{B}}(t) + NP_{\text{R}}(t). \quad (24)$$

Using (17) and (19) we can write

$$R(t) = \int_{-\infty}^t I(s)S(s)L_{\text{LB}}(t-s) ds. \quad (25)$$

It is appropriate to use the weighting scheme from the basic model,

$$W(s, t) = S(s)L_{\text{LB}}(t-s), \quad (26)$$

since $W(s, t)$ is now proportional to the probability, at time $s < t$, that individuals are classified as *recently infected* at time t if they become infected at time s and are living at time t , regardless of whether they are non-progressors or progressors. Then the weighted incidence, denoted I_{W} , is given by

$$\begin{aligned} I_{\text{W}}(t) &= \frac{\int_{-\infty}^t I(s)S(s)L_{\text{LB}}(t-s) ds}{\int_{-\infty}^t S(s)L_{\text{LB}}(t-s) ds} \\ &= \frac{R(t)}{\int_{-\infty}^t S(s)L_{\text{LB}}(t-s) ds}. \end{aligned} \quad (27)$$

The populations of *below-threshold* (B) and *above-threshold* (A) individuals are related to the populations defined in Figure 3C by

$$B(t) = P_{\text{B}}(t) + NP_{\text{R}}(t) + NP_{\text{L}}(t) \quad (28)$$

and

$$A(t) = P_A(t). \quad (29)$$

This means that the population of recent infections is related to the below- and above-threshold populations by

$$R(t) = B(t) - \epsilon A(t). \quad (30)$$

Writing the incidence estimate at time $t = 0$, performing the same expansion technique as before and assuming a constant susceptible population gives the simple expression

$$I_w = \frac{B_0 - \epsilon A_0}{S_0 \mathbb{E}[\tau_{LB}]}. \quad (31)$$

This expresses the incidence in terms of the calibration parameters $\mathbb{E}[\tau_{LB}]$ and ϵ , and the state variables S , B and A .

All that has changed, as a result of allowing non-progressors into the model, is the shift in the numerator from B_0 to $R_0 = B_0 - \epsilon A_0$. The same bias calculations as before apply immediately, but there is an increase in statistical sensitivity. This can be understood by noting that the gross error in B_0 becomes the dominant part of a fractional error in R_0 and that R_0 is smaller than B_0 .

3 Statistics and Calibration

The population models of the preceding section, which are of the well known deterministic ODE type, are expected to be in ever closer correspondence to a real population as the population size increases. To model the sampling process of a cross-sectional survey with a sample size N , we rescale the sub-populations of the ODE model, at any time t , by the total population size $T = S + B + A$, to obtain the population proportions $\mathbb{P}_S = S/T$, $\mathbb{P}_A = A/T$ and $\mathbb{P}_B = B/T$. The result of a survey employing the TRI is the set of three counts $N_S + N_B + N_A = N$. These counts are multinomially distributed around their means $\bar{N}_S = \mathbb{P}_S N$, $\bar{N}_B = \mathbb{P}_B N$ and $\bar{N}_A = \mathbb{P}_A N$. These observed counts turn equation (31) into an estimator for the recently weighted incidence I_{est} given by

$$I_{\text{est}} = \frac{1}{\mathbb{E}[\tau_{LB}]} \frac{N_B - \epsilon N_A}{N_S}. \quad (32)$$

Statistical Fluctuations

As noted in the preceding section, in a relatively established epidemic where the smallest class is B, the major source of fluctuations in I_{est} is N_B . Crudely speaking then, we can estimate the reproducibility by blaming all the statistical uncertainty on the measurement of N_B , which has a standard deviation $\sigma(N_B) = \sqrt{N\mathbb{P}_B(1 - \mathbb{P}_B)}$. This leads to the ‘back of the envelope’ formula for the relative standard deviation given by

$$\frac{\sigma(I_{\text{est}})}{I_{\text{est}}} \approx \frac{1}{\mathbb{P}_B - \epsilon\mathbb{P}_A} \sqrt{\frac{\mathbb{P}_B}{N}}. \quad (33)$$

However, all counts in the estimator (32) fluctuate and are correlated since they are constrained to add up to the sample size N . In the Appendix we demonstrate how the sample process can be reduced to two *independent* draws (α_1 and α_2) from a standard normal distribution. We obtain the stochastically estimated incidence by inserting the

counts, as functions of α_1 and α_2 into (32). Organising the resulting expression into a natural expansion in powers of $1/\sqrt{N}$ gives

$$I_{\text{est}}(\alpha_1, \alpha_2) = I_{\text{est}}(0, 0) - \frac{1}{\sqrt{N}} \left[\alpha_1 \frac{\gamma_1(\mathbb{P}_B - \epsilon\mathbb{P}_A)}{\mathbb{P}_S^2(\mathbb{P}_A + \mathbb{P}_B)} + \alpha_2 \frac{\gamma_2(1 + \epsilon)}{\mathbb{P}_S} \right] \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} + O\left(\frac{1}{N}\right). \quad (34)$$

The leading term,

$$I_{\text{est}}(0, 0) = \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} \frac{\bar{N}_B - \epsilon\bar{N}_A}{\bar{N}_S} = \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} \frac{\mathbb{P}_B - \epsilon\mathbb{P}_A}{\mathbb{P}_S}, \quad (35)$$

is just the estimator evaluated at the expectation values of the counts. The $O(1/N)$ term, which we have omitted, contains a term proportional to α_1^2 . This means that there is in principle a finite sample size bias in the estimator, which is however suppressed by $O(1/N)$ relative to the dominant term, as is borne out by the numerical calculations of the following section. The retained sub-leading term (of order $O(1/\sqrt{N})$) is distributed according to a bivariate normal distribution. Thus, to this order, there is no bias and we can read off

$$\frac{\sigma(I_{\text{est}})}{I_{\text{est}}(0, 0)} = \sqrt{\frac{1}{N} \frac{1}{\mathbb{P}_A + \mathbb{P}_B} \left(\frac{1}{\mathbb{P}_S} + \frac{\mathbb{P}_A\mathbb{P}_B(1 + \epsilon)^2}{(\mathbb{P}_B - \epsilon\mathbb{P}_A)^2} \right)}. \quad (36)$$

Comparison with numerical simulations suggests that this approximate result is essentially indistinguishable from the exact answer in the regime of realistic values for N the proportions (\mathbb{P}_S , \mathbb{P}_B and \mathbb{P}_A), given that in practice one uses the sample proportions as estimates of the population proportions.

Figure 4 plots the relations (33) and (36) for different values of \mathbb{P}_{NP} and fixed values of \mathbb{P}_S , \mathbb{P}_A and \mathbb{P}_B . Comparison with Figure 2 confirms that the truncation of the expansion of the susceptible population to a constant term (the crucial step in obtaining the simple incidence relation on which the estimator is based) leads to a bias that is small compared to realistic statistical errors. The close correspondence between the two curves suggests that the simple formula (33) is more than sufficiently accurate to choose a sample size for an intended study, if not sufficiently accurate to use as the basis of an error analysis of real data.

Calibration

Aside from the sample counts N_S , N_B and N_A , all other quantities in relations of the kind derived in the previous section, such as $\mathbb{E}[\tau_{\text{LB}}]$ in the estimator, should be regarded as calibration information that needs to be estimated independently of a cross-sectional survey used to infer incidence. Even in the general case, where the population of susceptibles is allowed to vary considerably over the time when the weighting function is non-vanishing, calibration consists only of estimating \mathbb{P}_{NP} and expressions of the form $\mathbb{E}[\tau_{\text{LB}}^n]$. We have already remarked that it will probably not be possible to obtain reasonable estimates of $\mathbb{E}[\tau_{\text{LB}}^n]$ for values of n other than 1 and that it appears that only this term is really needed for practical purposes.

Note that if one wishes merely to estimate *trends* in incidence, as opposed to absolute incidence values, then it is not necessary to have an estimate for $\mathbb{E}[\tau_{\text{LB}}]$ at all, since it is just an overall factor. If the overall scale of incidence estimates is to be known, considerable effort will need to be invested in the estimation of $\mathbb{E}[\tau_{\text{LB}}]$. Note that it is, strictly speaking, the mean time spent in the *living, below-threshold* state

and hence requires thoughtful data censoring in any observation of a cohort. There is also difficulty in establishing good estimates for individual times spent below threshold post-infection. Any quantitative assay (and the BED assay in particular) is likely to progress very non-linearly with time for a while after infection and hence extrapolation of observed values to putative infection times is dubious. It may make sense to introduce an explicit *lower bound* threshold which lies inside the regime where individual data sets admit curve fitting. This appears to be equivalent to defining incidence as the rate at which individuals cross the lower threshold, rather than the rate at which they become infected. As long as the typical delay between infection and crossing a lower threshold is small compared to other relevant time scales, this would introduce no meaningful difference to the model or its interpretation.

However, surveys conducted at different times will not yield comparable values of $I_{\text{est}} = R/S$ unless ϵ (equivalently \mathbb{P}_{NP}) is known with some accuracy, since it appears in one of two terms in the numerator. Consider two surveys designed to estimate incidence at different times or places where the same calibration is assumed to apply. The first survey obtains values of $N_S^{(1)}$, $N_B^{(1)}$ and $N_A^{(1)}$ and the second obtains values of $N_S^{(2)}$, $N_B^{(2)}$ and $N_A^{(2)}$. Assume a calibrated value of

$$\epsilon = \epsilon_0 + \epsilon_1, \quad (37)$$

where ϵ_0 is the real value and ϵ_1 is the error in this estimate due to the total effect of methodological and statistical factors. This leads, on average, to an estimate of the difference between the two incidences of

$$\Delta I_{\text{est}}(\epsilon) = I_{\text{est}}^{(1)}(\epsilon) - I_{\text{est}}^{(2)}(\epsilon) = \frac{N_B^{(1)} - \epsilon N_A^{(1)}}{N_S^{(1)} \mathbb{E}[\tau_{\text{LB}}]} - \frac{N_B^{(2)} - \epsilon N_A^{(2)}}{N_S^{(2)} \mathbb{E}[\tau_{\text{LB}}]}.$$

Knowledge of the exact value ϵ_0 leads to

$$\Delta I_{\text{est}}(\epsilon_0) = I_{\text{est}}^{(1)}(\epsilon_0) - I_{\text{est}}^{(2)}(\epsilon_0) = \frac{N_B^{(1)} - \epsilon_0 N_A^{(1)}}{N_S^{(1)} \mathbb{E}[\tau_{\text{LB}}]} - \frac{N_B^{(2)} - \epsilon_0 N_A^{(2)}}{N_S^{(2)} \mathbb{E}[\tau_{\text{LB}}]},$$

from which we see that the error in ΔI_{est} , due to the error in ϵ , is

$$\Delta I_{\text{est}}(\epsilon) - \Delta I_{\text{est}}(\epsilon_0) = \frac{\epsilon_1}{\mathbb{E}[\tau_{\text{LB}}]} \left(\frac{N_A^{(2)}}{N_S^{(2)}} - \frac{N_A^{(1)}}{N_S^{(1)}} \right). \quad (38)$$

This means that real trends in incidence tend to be incorrectly estimated due to imperfect calibration. The direction and magnitude of error depend in detail on many factors, such as population renewal and long term survival post infection. We cannot summarise all the possible effects that this may produce, but present Figure 5 as an indication of what can happen.

4 Numerical Simulations

In this section we briefly outline two numerical simulations. The first serves to test the accuracy of the bias and standard deviation estimates derived from the truncation of the systematic expansion of the stochastic estimator $I_{\text{est}}(\alpha_1, \alpha_2)$ and the second demonstrates the use of the simple expression (32) for incidence estimation.

The first simulation consists of a monte-carlo experiment. At each iteration, two standard normal variables are drawn. Counts for susceptible, below-threshold and

above-threshold sub-populations, within a sample of size N , are generated according to the procedure provided in the Appendix. This incorporates the assumption that the multinomial distribution of the sample proportions can be approximated as normal, but involves no truncation of the estimator in powers of $1/\sqrt{N}$. An ensemble of 10,000,000 point estimates I_{est} produces suitably converged estimates for the mean and standard deviation.

The entire procedure of the preceding paragraph was repeated for values of $\mathbb{P}_A \in [0.1, 0.5]$. For each value of \mathbb{P}_A , the value of \mathbb{P}_B was varied to produce an incidence in the range $[0.01, 0.2]$. A sample size of $N = 5000$ was used. The average fractional discrepancy between the mean incidence and $I_{\text{est}}(0, 0)$ was 0.0003, with values ranging from 0.00001 to 0.0008, confirming that the intrinsic sampling bias is of order $1/N$. The average fractional discrepancy between the observed standard deviation of the incidence and the approximate expression (36) was 0.0006, with values ranging from 0.00004 to 0.001, which is also consistent with the truncation at $O(1/\sqrt{N})$. Note we have no simple rule for directly estimating the error in standard deviation produced by the truncation.

The second simulation models a susceptible population becoming infected. Arrival times of new infections are generated according to a non-homogeneous Poisson process with intensity given by $\lambda(t) = S(t)I(t)$. Newly infected individuals are initially classified as below the recency threshold of a TRI. A fraction $1 - \mathbb{P}_{\text{NP}}$ progresses to the above-threshold category according to a waiting time f_B (conditional on survival). Weibull functions are used for the waiting time distributions f_B and f_L . Unique individuals can be drawn from the population at intervals, to produce counts N_A , N_B and N_S , and hence estimates for incidence.

To demonstrate the incidence estimation process, a 50 year population scenario was produced. Figure 6 shows the Weibull distributions used for f_B and f_L (top) and the corresponding survival curves L_B and L_L (bottom). The Weibull shape and scale parameters for the distributions were chosen to give approximately realistic values for the mean and standard deviations for the window period and infected life expectancy, as detailed in Table 1. The susceptible population was set to $S(t) = 100,000 + 5,000t$, with t measured in years. The incidence was set at 0.01 (hazard per person per year) for the first ten years, climbing linearly to 0.1 over the next ten years, then remaining at this high level for a further ten years, followed by ten years of linear decline to 0.03 and maintained at this level for the last ten years of the simulation.

	Shape (k)	Scale (l)	Mean	Standard Dev.
Window period	8	0.58	200 days	30 days
Life expectancy	4.5	8.83	8 years	2 years

Table 1: Weibull parameters for the Monte Carlo simulation

Figure 7 shows output from this simulation. The input incidence parameter is indicated as the dotted *instantaneous incidence* curve. A sample of 5,000 individuals was surveyed every year, and an incidence estimate was produced using the simple estimator (32) with exact values of $\mathbb{E}[\tau_{\text{LB}}]$ and \mathbb{P}_{NP} , i.e., assuming perfect calibration. These point estimates are indicated as *estimated incidence* values, using ‘+’ symbols. The combined effects of the previously noted time convolution, in I_W , as well as stochastic departure from means in the simulated population, make the input incidence parameter an unrealistic target for simulated incidence measurements. Thus, the solid *weighted incidence* line has been displayed, which uses full knowledge of all population members’

classification into S , A or B , inserted into (31) with full knowledge of the denominator, (both the non-constant $S(t)$ and the exact L_{LB}). This is essentially all that the incidence estimation algorithm can be asked to reproduce. A *two standard deviation envelope* around the *weighted incidence* line, calculated from (36) using knowledge of the full population, is shown as two dashed lines.

5 Discussion and Conclusion

We have presented a detailed analysis of relations between recent incidence in a population and counts of ‘recently infected’ individuals. These are in principle complex convolutions involving the epidemiological history as well as all information about the distribution of waiting times in the recently infected category. When the susceptible population undergoes realistically modest variation on the time scale of the definition of recency implied by the TRI, we obtain simplified forms which incur very little error. The simplified relations form the basis of estimators which are shown to have considerably more variance than bias under realistic demographic and epidemiological assumptions.

A limitation of the current model is that it assumes only one direction of progression of individuals from an experimentally defined state of ‘recent’ infection to ‘non-recent’ infection. The reverse apparently occurs for BED optical density in some terminal stage AIDS patients. This process constitutes a substantial complication, and further work is required to investigate how it may be incorporated into an analytical model of the kind developed here. It may be worth exploring previous suggestions [8] to use additional information, from questionnaires or other assays, to remove end-stage patients from the observed recent count. We have also not considered the possibility that calibration parameters are functions of time, for example as a result of substantial vaccine uptake in a population. Even more subtle is a point raised under calibration, namely that imperfect estimation of the non-progressing fraction of the population leads to a complex bias in incidence estimates. This bias is dependent on factors not even present in the incidence estimator, such as long term survival post infection.

A key observation is that for the purposes of estimating incidence from a TRI, there is no fundamental obstacle posed by having a known fraction of individuals fail to progress out of the state of ‘recent infection’, as long as their distribution of survival times from infection is the same as in the progressing population. In fact, knowledge of this non-progressing fraction alone, without knowledge of the mean duration of the ‘recently infected’ state (in the progressing sub-population where it is finite) is sufficient (and necessary) to infer *trends* in incidence. This could possibly be estimated for the BED assay from historical records, since there are many viable samples in storage with supporting clinical information indicating long-infected status. The mean of the finite waiting times is however required in order to estimate *absolute values* of incidence. Prospective follow-up is probably the only practical way to estimate this parameter.

A noteworthy difference between the calibration method we have proposed and the sensitivity/specificity calibration method currently favoured by some workers [8] developing the use of the BED assay is that the our proposed methodology is a direct calibration of the parameters of a *process*, which are in principle not dependent on the epidemiological state of a population, unlike the sensitivities and specificities inferred from scatter plots from observational cohorts. These dependencies arise from the very same convolutions which we noted are inescapable in the definition of ‘recent incidence’. They involve non-constant distributions of ‘times since infection’ which are available

for being sampled in different surveys, such as during calibration and subsequent attempted incidence estimation. We propose a detailed assessment of this effect under a variety of epidemiological and demographic assumptions to evaluate its importance.

Besides the explicit assumptions noted, the analysis presented here is quite general. Tests for recent infection continue to be of interest, and new assays are likely to be developed both for HIV infection and other important diseases. In summary, we have presented a detailed analysis of a likelihood function which can inform design of appropriate calibration studies and cross-sectional incidence estimation surveys, and can also form the basis of systematic inference algorithms for processing the data obtained from such surveys.

Acknowledgements

The authors wish to thank John Hargrove and Norman Ives for useful discussions exploring the ideas contained in this article.

Appendix

Given a sample of N subjects tested using the TRI, we derive a systematic expansion, in powers of $O(1/\sqrt{N})$, for the estimator

$$I_{\text{est}} = \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} \frac{N_{\text{B}} - \epsilon N_{\text{A}}}{N_{\text{S}}}, \quad (39)$$

where the counts N_{X} fluctuate multinomially around their means $\bar{N}_{\text{X}} = \mathbb{P}_{\text{X}}N$, with standard deviations $\sigma_{\text{X}} = \sqrt{N\mathbb{P}_{\text{X}}(1 - \mathbb{P}_{\text{X}})}$. In order to account for fluctuations and their correlations we express the three counts as the result of two independent random draws. We assume the counts are sufficiently large so that binomial distributions can be approximated by normal distributions — this is always the case if the survey is to have any reasonable accuracy.

- Draw a number α_1 from a standard normal distribution and set

$$N_{\text{S}} = \bar{N}_{\text{S}} + \sigma_1 \alpha_1, \quad (40)$$

where

$$\sigma_1 = \sigma_{\text{S}} = \sqrt{N\mathbb{P}_{\text{S}}(1 - \mathbb{P}_{\text{S}})} = \sqrt{N}\gamma_1. \quad (41)$$

Defining γ_1 allows us to keep track of powers of $1/\sqrt{N}$.

- Draw a number α_2 from a standard normal distribution and set

$$N_{\text{B}} = \mathbb{P}'_{\text{B}}(N - N_{\text{S}}) + \sigma_2 \alpha_2 = \mathbb{P}'_{\text{B}}N(1 - \mathbb{P}_{\text{S}}) - \mathbb{P}'_{\text{B}}\sigma_1 \alpha_1 + \sigma_2 \alpha_2 \quad (42)$$

and

$$N_{\text{A}} = \mathbb{P}'_{\text{A}}(N - N_{\text{S}}) - \sigma_2 \alpha_2 = \mathbb{P}'_{\text{A}}N(1 - \mathbb{P}_{\text{S}}) - \mathbb{P}'_{\text{A}}\sigma_1 \alpha_1 - \sigma_2 \alpha_2 \quad (43)$$

where

$$\mathbb{P}'_{\text{B}} = \frac{\mathbb{P}_{\text{B}}}{\mathbb{P}_{\text{B}} + \mathbb{P}_{\text{A}}} \quad \text{and} \quad \mathbb{P}'_{\text{A}} = 1 - \mathbb{P}'_{\text{B}} \quad (44)$$

are the probabilities of an individual being in B and A given that they are not in S and

$$\sigma_2 = \sigma_{B|\alpha_1} = \sqrt{(N - N_S)\mathbb{P}'_B\mathbb{P}'_A} = \sqrt{N}\gamma_2 \left(1 + O\left(\frac{1}{\sqrt{N}}\right)\right) \quad (45)$$

is the standard deviation of N_B (and N_A) subject to α_1 having been determined, so that

$$\gamma_2 = \sqrt{\frac{\mathbb{P}_A\mathbb{P}_B}{\mathbb{P}_A + \mathbb{P}_B}}. \quad (46)$$

Note that this procedure works independently of the order in which the values of N_S , N_B and N_A are assigned from the random α 's. We can explicitly insert this decomposition into the expression for I_{est} to obtain an expression for the estimator in terms of two independent draws from a standard normal distribution. Keeping only the $O(1)$ and $O(1/\sqrt{N})$ terms explicit leads to

$$I_{\text{est}}(\alpha_1, \alpha_2) = I_{\text{est}}(0, 0) - \frac{1}{\sqrt{N}} \left[\alpha_1 \frac{\gamma_1(\mathbb{P}_B - \epsilon\mathbb{P}_A)}{\mathbb{P}_S^2(\mathbb{P}_A + \mathbb{P}_B)} + \alpha_2 \frac{\gamma_2(1 + \epsilon)}{\mathbb{P}_S} \right] \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} + O\left(\frac{1}{N}\right), \quad (47)$$

where

$$I_{\text{est}}(0, 0) = \frac{1}{\mathbb{E}[\tau_{\text{LB}}]} \frac{\mathbb{P}_B - \epsilon\mathbb{P}_A}{\mathbb{P}_S}. \quad (48)$$

Two key observations immediately follow:

- The proposed I_{est} is a consistent estimator in the sense that terms with bias are at least $O(1/N)$ suppressed relative to the dominant term.
- To order $O(1/\sqrt{N})$, I_{est} is Gaussian with relative variance

$$\left(\frac{\sigma(I_{\text{est}})}{I_{\text{est}}(0, 0)}\right)^2 = \frac{1}{N} \frac{1}{\mathbb{P}_A + \mathbb{P}_B} \left(\frac{1}{\mathbb{P}_S} + \frac{\mathbb{P}_A\mathbb{P}_B(1 + \epsilon)^2}{(\mathbb{P}_B - \epsilon\mathbb{P}_A)^2}\right). \quad (49)$$

References

- [1] Brookmeyer R. and Quinn T.C. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. *American Journal of Epidemiology*, 141(2):166–172, 1995.
- [2] Posner S.J. et al. Estimating HIV incidence and detection rates from surveillance data. *Epidemiology*, 15:164–172, 2004.
- [3] Jannssen R.S. et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA*, 280(1):42–48, 1998.
- [4] Parekh B.S. et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent hiv infection and estimating incidence. *AIDS Research and Human Retroviruses*, 18(4):295–307, 2002.
- [5] Parekh B.S. and McDougal J.S. New approaches for detecting recent HIV-1 infection. *AIDS Rev*, 3:183–193, 2001.
- [6] Cole S.R., Chu H., and Brookmeyer R. Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data. *American Journal of Epidemiology*, 165(1):94–100, 2006.

- [7] Nascimento C.M.R. et al. Estimation of HIV incidence among repeat anonymous testers in Catalonia, Spain. *AIDS Research and Human retroviruses*, 20(11):1145–1147, 2004.
- [8] McDougal J.S. et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. *AIDS Research and Human Retroviruses*, 22(10):945–952, 2006.
- [9] K. Wong, Tsai W., and Kuhn L. Estimating HIV hazard rates from cross-sectional HIV prevalence data. *Statistics in Medicine*, 25(11):2441–2449, 2006.
- [10] Hargrove J. W. et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. *AIDS*, To Appear, 2008.




Figure 1:

- A) Hypothetical individual BED optical density (OD) as a function of time since infection.
- B) Hypothetical collection of individual OD progression plots with inter-individual variability and an arbitrary OD threshold which can be used to define *recent infection*.
- C) Hypothetical distribution of times spent below an OD threshold after infection, approximately corresponding to the mean and variance of the sample of individual progression curves in B).




Figure 2: Fractional error in the simple incidence relation (16) versus the full relation (15), as a function of growth rate of susceptible population, quoted as a percentage annual growth. The scenario is defined by: $S(t) = S(0)e^{\alpha t}$ and f_{LB} is a Weibull distribution with scale parameter $l = 0.57$ and shape parameter $k = 8$. α is varied to produce deviation from constant susceptibles ($\alpha = 0$) in which limit equation (16) is exact.




Figure 3:

- A) The basic epidemiological/TRI progression model. Members of the susceptible population S are subject to a per unit time hazard (incidence) I of infection. After infection, individuals enter the below threshold population B . Here they spend a time distributed according to f_B (conditional on survival), after which they spend the remainder of their lifetime in the above threshold population A .
- B) The basic model modified to accommodate non-progressors on the TRI. Now, upon infection, a proportion \mathbb{P}_{NP} of individuals remain forever below the threshold of the TRI, i.e., they enter the NP category. The remaining proportion $1 - \mathbb{P}_{NP}$, the progressors, are assigned a waiting time from the same distribution f_B as in the basic model, and spend this time in the ‘progressing, below threshold’ population P_B . Those that survive long enough spend the remainder of their lifetime in the ‘progressing, above threshold’ population P_A .
- C) Modified model with separation of non-progressors into ‘recent’ and ‘long’ infected categories. This model contains the same epidemiology and biology as the model in B), with the introduction of a bookkeeping device which facilitates the definition of a calibratable category of ‘recently infected’ individuals. The non-progressors are assigned waiting times drawn from the distribution observed in the progressing population, and spend this waiting time (again conditional on survival) in the ‘non-progressing recent’ (NP_R) category.




Figure 4: Plots of the crude formula (33) (dashed line) and the systematic formula (36) truncated after $O(1/\sqrt{N})$ (solid line) for the standard deviation of incidence estimates, expressed as a fraction of the leading term $I_{\text{est}}(0, 0)$, and plotted as a function of the non-progressing fraction \mathbb{P}_{NP} , for fixed values $\mathbb{P}_{\text{A}} = 0.35$, $\mathbb{P}_{\text{B}} = 0.05$ and $\mathbb{P}_{\text{S}} = 0.60$.




Figure 5: Expectation value of observed difference in incidence from two surveys, as a function of possible values of a calibration estimate for \mathbb{P}_{NP} , given a true value of $\mathbb{P}_{\text{NP}} = 0.05$, and assuming $\mathbb{E}[\tau_{\text{LB}}]$ is known. The context of the two hypothetical surveys is defined as year 30 and year 35 in the scenario described in detail in the numerical simulations section. Rounded to the level reported here, this leads to the values $I_{\text{est}}^{(1)} = 0.100$, $I_{\text{est}}^{(2)} = 0.068$, $\mathbb{P}_{\text{A}}^{(1)} = 0.373$, $\mathbb{P}_{\text{B}}^{(1)} = 0.051$, $\mathbb{P}_{\text{S}}^{(1)} = 0.576$, $\mathbb{P}_{\text{A}}^{(2)} = 0.357$, $\mathbb{P}_{\text{B}}^{(2)} = 0.041$ and $\mathbb{P}_{\text{S}}^{(2)} = 0.602$. Note that the expectation value of the observed difference is correct when the calibration estimate of \mathbb{P}_{NP} is the true value. The plot can be rescaled to indicate expected values of *fractional* decline in incidence, thus simulating trend estimation in the absence of a known value for $\mathbb{E}[\tau_{\text{LB}}]$.




Figure 6: Graphical representation of the densities f_L and f_B for survival times and times below threshold (conditional on survival) in the progressing population (top) and the corresponding survival probabilities L_L and L_B (bottom). Parameters for these curves are detailed in Table 1.




Figure 7: Full stochastic simulation of population with epidemic, individual survival times, and annual sampling of 5,000 individuals. The susceptible population was set to $S(t) = 100,000 + 5,000t$ with time measured in years. The *instantaneous incidence* parameter is the dotted curve. The target of the estimates is the *weighted incidence* (solid line), which was calculated explicitly as per (31) from all the known inputs. This is flanked by a *two standard deviation envelope* (dashed lines). Simulated *estimated incidence* (+ symbols) were obtained by using sample counts in the simple estimator (32). The calibration parameters $\mathbb{E}[\tau_{LB}]$ and \mathbb{P}_{NP} were assumed to be known exactly.